Immunocore (NASDAQ:IMCR) Issues Earnings Results, Beats Estimates By $0.25 EPS

Immunocore (NASDAQ:IMCR) posted its earnings results on Thursday. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.25, Briefing.com reports. Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The business had revenue of $75.40 million for the quarter, compared to the consensus estimate of $74.58 million. During the same period last year, the company earned ($0.37) EPS. The firm’s revenue was up 26.2% compared to the same quarter last year.

Immunocore Stock Performance

Shares of IMCR stock opened at $37.20 on Monday. Immunocore has a one year low of $33.04 and a one year high of $76.98. The company has a market cap of $1.86 billion, a P/E ratio of -30.49 and a beta of 0.75. The firm has a 50-day moving average of $38.43 and a 200-day moving average of $53.74. The company has a debt-to-equity ratio of 1.22, a current ratio of 5.96 and a quick ratio of 5.94.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of Immunocore in a research report on Monday, April 29th. JPMorgan Chase & Co. lowered their price objective on Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a research report on Wednesday, July 10th. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Wednesday, June 5th. Canaccord Genuity Group upped their price objective on shares of Immunocore from $63.00 to $67.00 and gave the company a “hold” rating in a research note on Thursday, May 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $81.00 price objective on shares of Immunocore in a research note on Friday. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.00.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.